, four times more than in the integrated procedure (18.5 × 10 8 ).
MNC purity (84.4% vs. 63.8%) and enrichment (27.9 vs. 5.9) in the product collected were also higher in the multistep procedure. The whole ECP time was higher in the multistep than in the integrated procedure (272 vs. 106 min), but the calculated time to collect 25 × 10 8 MNCs in the multistep was shorter compared with the one-step procedure (77.8 vs. 172 min). All these differences between the two protocols were statistically significant.
CONCLUSIONS: These two ECP protocols are different with respect to MNC collection and length of procedure. Some unresolved questions, such as the better MNC dose to inactivate or the number of consecutive days that ECP should be performed for optimal clinical efficacy, require further review.
E xtracorporeal photopheresis (ECP) is effective for treating bronchiolitis obliterans (BO)
, which presents as cell rejection in lung transplant patients, as well as graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). [1] [2] [3] Although its clinical efficacy has been proven, factors about ECP still remain unclear: first, its exact physiologic mechanism of action; second, the minimum number of cells that must be treated for ECP to be effective 4, 5 ; third, the treatment regimens (number of ECP days per cycle) required for effective ECP treatment; and fourth, whether an integrated or inline ECP protocol is better than a multistep or offline ECP system. Our study focused on the fourth issue but also suggests some hypotheses to try to resolve the second and third factors. The aim of this study was to compare an integrated or single-step ECP protocol (Therakos Cellex system; Mallinckrodt Pharmaceuticals) with a multistep or offline ECP system (Spectra Optia apheresis machine (Terumo BCT) for MNC collection and the Macogenic G2 system (Macopharma), with respect to the number of mononuclear cells (MNCs) and the enrichment and purity of the collected product.
As secondary objectives, some machine parameters were also evaluated, such as the time to perform the MNC collection or time to complete the whole ECP process. In addition, patient safety parameters were also evaluated.
MATERIALS AND METHODS

Study design
The study was designed as a prospective paired trial to validate the integrated ECP protocol using the Therakos Cellex system in our center. The features of this new ECP protocol were also compared against our routine ECP multistep system that uses the Spectra Optia apheresis machine for MNC collection and the Macogenic G2 system for subsequent ECP. The clinical effects of ECP were outside the scope of this study.
Patients
Patients who had already undergone ECP treatment were invited to participate in this study. For inclusion, participants were required to have undergone at least two previous ECP procedures. They were informed about adverse effects related to apheresis collection as well as ECP inactivation and MNC infusion. All the patients recruited for this study were required to give written informed consent to allow participation and use of their data. The study was approved by the Hospital Universitario Puerta de HierroMajadahonda Research Ethics Committee as an abridged procedure for nonexperimental studies. Because both systems carry the Conformité Européenne (CE) mark and are already approved for use in Spain, this was not considered an experimental clinical trial. Patients were evaluated by a physician before every ECP procedure. Systolic and diastolic blood pressure, heart rate, and temperature were recorded. Blood cell count, coagulation tests, creatinine, urea, sodium, potassium, chlorine, and calcium tests were performed in patients immediately before and after the ECP procedure.
Procedures
Because the ECP protocol for integrated and multistep protocols includes two ECP procedures on consecutive days (one cycle), the study was designed to perform the first procedure with one system and the second procedure with the other, thereby allowing paired comparison of the results. Procedure assignment was not randomized due to complex logistics within the Therapeutic Apheresis Unit; nevertheless, patients were assigned to begin treatment with one system or the other in equal proportions. The integrated ECP protocol was performed according to the Therakos Cellex operator's manual. The equipment was supplied with software v.3.0. Nurses underwent training by the company's staff for a period of five procedures that were not included in this study. The company staff also gave the nursing team support during the first procedures included in this validation. Briefly, the integrated Therakos Cellex ECP protocol includes a disposable MNC collection set that uses a single or double needle for blood collection and a Latham bowl for subsequent MNC concentrations. Procedures were set up to process 1500 mL of the patients' blood in a single cycle with the separated buffy coat collected in the bowl. Blood anticoagulation was performed using a 10 unit/mL heparin sodium dilution and 0.9% saline infused through a spike connection. After MNCs had been collected in the integrated bag, 20 μg 8-Metoxipsoralen (8-MOP)/mL of product were added through an injection port adapter (Metoxalene S.A.L.F. 0.1 mg/5 mL; SALF). The machine then carried out the illumination process using a multiplebatch method 6 and, finally, the inactivated MNCs were reinfused into the patient thorough the same vein access that was used for the blood collection. Patients remained connected to the machine from the moment that blood collection began until reinfusion was completed after MNC photoinactivation. The multistep process was performed using the Spectra Optia apheresis machine for MNC collection. Subsequent photo inactivation was performed using the Macogenic G2 system for extracorporeal photopheresis. This ECP protocol has been the standard used in our apheresis unit for the last 5 years. 7 Spectra Optia machine MNC collections are performed using disposable double-needle access sets and citrate blood anticoagulation (ACD-A) (Macopharma) with an ACD-A-to-blood ratio between 1:10 and 1:16. ACD-A and 0.9% saline solutions are infused to the Optia set though a spike connector that includes bacterial filters to ensure sterile connections. MNC are concentrated by separation belt centrifugation. This procedure was described previously. 8, 9 MNCs are sent from the separation belt to an integrated collection bag. Target collection was set to obtain 150 mL purified MNCs per procedure. After collection, MNC bags were sealed and sent to a cell-processing laboratory where 0.9% saline was added through a sterile tubing connection (TSC II Terumo BCT) to obtain 300 mL total volume and a maximum 2% hematocrit in the product. Next, 20 μg 8-MOP/mL of product were injected into the bag via a Luer connection. The previously described procedures were carried out under sterile conditions inside a laminar flow hood. The bags were then illuminated using the Macogenic G2 photo-inactivation system for ECP. 10 This ECP method is defined as a single-batch method. 6 Finally, the inactivated product was reinfused into the same patient using our standard transfusion protocol. (Table 1) .
Additional information about vein access, excluded patients, unfinished procedures, MNC product analysis, and patient parameter definitions are included in the Supplementary Methods.
RESULTS
Patients
A total of 14 patients were recruited for the study (9 male and 5 female), of whom 3 had GVHD after HSCT and 11 had BO after lung transplant. The mean age at first ECP was 55.9 years (range 27.9-67.2). All patients underwent at least one ECP with the multistep and another with the integrated procedure. One patient repeated the sequence three times (six procedures) and another twice (four procedures). The machine assignment order was comparable in the two groups, and a total of 17 pairs of procedures were performed; however, one multistep process procedure was excluded from the study because apheresis was performed on a machine other than the Optia. In addition, one integrated procedure remained unfinished due to unrecoverable vein access in a Cellex machine group patient. Both pairs of failed and unfinished procedures were excluded from the study. Central or peripheral vein access and vein assignment were also comparable in the two groups. Finally, 15 pairs of procedures were fully analyzed. Four procedures in the Cellex group were performed using a single-needle access (23.5%) versus 100% in the Optia group (p value not significant). No significant differences were found between the two groups with respect to patient characteristics that included TBV and blood and preprocedure biochemical parameters. This was a paired study comparing the procedures in the same patient group; therefore, procedure assignment and preprocedure parameters in the two groups were comparable. Hematocrit and platelet counts before donations and on days between donations were also comparable, and no statistical differences were found. MNCs circulating in patient blood volumes before apheresis procedures (MNC in patient TBV) were 81.7 × 10 8 in both groups.
Median cubital veins were more frequently used for blood drawing and radial veins for return. Some differences were observed in patient blood tests after the procedure; however, they are not fully comparable because Cellex blood samples were taken after the MNC infusion rather than before as in the Optia system (data not shown).
Procedure, products, and adjusted parameters TBV processed in the Optia protocol was five times higher than in Cellex. Anticoagulant volume, MNC collection time, and whole ECP time in Optia were also higher, but inactivation and infusion time were lower in Cellex. The percentage of MNCs collected in relation to the number circulating in the patients before apheresis (MNC captured per procedure) was about four times higher in Optia (Table 1) . MNC product volume collected in Cellex (Table 2 ) was higher than in Optia. And the total MNC per product in Optia was approximately four times higher than in Cellex together with higher MNC purity and MNC enrichment, which was 4.7 times higher in Optia. However, the Optia product showed higher hematocrit and platelet concentrations. Regarding the procedure-adjusted parameters (Table 1) , Optia needed less time to collect the same MNC number compared with Cellex, but the blood volume needed to collect a prefixed MNCs dose was comparable between both machines.
Adverse reactions in patients
Optia procedures showed fully recovered vein access alarms in 2 of 16 procedures (11.7%). Of 16 patients, 9 (56.2%) required treatment with calcium supplements due to minor hypocalcemia symptoms that did not require termination of the procedure. As previously described, one Cellex procedure was not finished due to unrecoverable vein access. In addition, 3 of 16 (18.7%) Cellex procedures provoked flow alarms that fully recovered. However, patients tolerated the procedure well, and neither hypovolemic nor hemorrhagic effects were presented during the study.
DISCUSSION
This study compared an integrated or one-step system with a multistep or offline ECP protocol in the same patient group, particularly focusing on MNC collection parameters and the quality of the MNC products. The principal finding was that the multistep ECP protocol collects and inactivates about four times more MNCs than the Cellex one-step protocol. This indicates that the two protocols are clearly different, with Optia procedures taking longer but processing higher blood volumes and obtaining greater numbers and more purified MNCs.
Procedure and MNC product
The number and concentration of MNCs collected with the Optia were higher than with the Cellex, as was the cell purity of the product. In addition, MNC enrichment was 4.7 times higher with the Optia, indicating the cell products from procedures carried out with the Cellex machine contained a higher proportion of granulocytes. The Optia product had a higher platelet and red cell concentration, in accordance with the MNC enrichment. When the adjusted parameters were analyzed, we found that Optia collects MNCs more quickly. Perhaps one of the most interesting parameters evaluated was the MNCs captured per procedure. This parameter evaluates the percentage of primary MNCs circulating in the patient TBV before apheresis that are subsequently collected by the machine. Our results suggest that Optia collected almost all (94%) the circulating MNCs; however, Cellex only collected about 20%. This is interesting because, in a protocol that includes two ECP treatments on two consecutive days (one cycle), most of the MNCs collected on Day 2 would be the same as those collected and inactivated the day before. From previous studies we know that blood cells do not behave as a stable population in the bloodstream, and mobilization was previously described for both leukocytes 4 and platelets after platelet pheresis procedures. 11 Global analysis shows that the Optia protocol collects MNCs more quickly and obtains a higher quality MNC product than Cellex. These findings could be explained by the MNC collection belt used in Optia, a more recent technology than the Latham bowl system used in Cellex.
Patient safety
Both protocols were well tolerated, and although the sample size in this study does not allow firm conclusions regarding patient safety, no statistically significant differences were found between the two protocols. The Optia multistep procedure used citrate as an anticoagulant, whereas the Cellex protocol used heparin. In Optia procedures, hypocalcemia is frequent but tolerable. In contrast, Cellex had prolonged postprocedure coagulation tests, although without hemorrhagic consequences. Vein access issues were the most challenging problems in both protocols and mainly solved by using a central vein access. This strategy cannot be regarded as a complete solution because catheters present a higher risk of infection compared with peripheral vein access. The Cellex single-needle protocol presents a remarkable advantage in this respect compared with the Optia protocol, especially for patients with poor vein access. In addition, the most notable advantage of Cellex is its integrated ECP system that avoids the risk of errors when MNCs are reinfused into the patient, which is possible when a multistep protocol is used. Regarding patient and product manipulation sterility, the Cellex ECP protocol, although integrated, cannot be considered a closed system: the infusion of saline, anticoagulant, and 8-MOP are carried out through spike ports without bacterial filters that can compromise product sterility and require careful aseptic manipulation. On the contrary, the Optia set spike ports include bacterial filters, and MOP-8 infusion is performed under sterile conditions inside a laminar flow hood. Finally, regarding ECP treatment exclusion criteria, the Cellex protocol does not allow ECP procedures to be performed in patients with low hematocrit levels (below 25%). This is not an exclusion criterion for Optia and should be taken into consideration because some patients, especially those with GVHD, have hematocrit levels lower than 25% and thus cannot be candidates for Cellex procedures.
Strengths and weakness of the study
One of the main strengths of our study is the paired comparison of the procedures in the same patients for two different ECP protocols. This allowed us to establish conclusions with a low number of patients. However, the low number of patients does not allow conclusions to be drawn regarding clinical results or adverse events in either protocol. Although clinical evaluation of the patients was not an objective of this study, this is obviously a relevant weakness. We previously published results of our multistep ECP protocol in lung rejection patients affected by BO. 7 In spite of this, some clinical inferences are feasible from our analysis that confirm the clinical efficacy of our multistep protocol and other studies that confirm the one-step efficacy of the Cellex protocol. 1 Another weakness of the study that deserves some comments is that it was performed during the implementation in our center of the one-step system, in contrast to the multistep system that was well known by our staff. However, we think this limitation had only a slight effect on the results and conclusions obtained from the study.
Mechanism and implications for clinicians and policymakers
Our patient treatment protocol includes ECP procedures on two consecutive days (one cycle) per week during the first month, then one cycle ECP every 2 weeks for 2 months, followed, if the patient improves, by one cycle ECP per month. One question that remains unsolved until now is if it is necessary to perform ECP procedures on two consecutive days.
Our results suggest that almost all the circulating MNCs in the blood of the patient are captured in one Optia ECP protocol procedure (94.6%), whereas only 22.2% are captured in a Cellex procedure. It seems clear that performing Optia ECP procedures on consecutive days would collect and inactivate MNCs that had undergone ECP the day before. This suggests that the second consecutive ECP treatment may be unnecessary when the Optia protocol is used. This hypothesis is also supported because the Macopharma ECP system multistep protocol performs a single-batch 6 inactivation and thereby ensures that all MNCs are illuminated. In contrast, the multiple-batch process used with Cellex, 6 where MNCs recirculate during the illumination process, does not ensure illumination of all the MNCs in the bag product.
We are aware that any decision to change from a two consecutive-day protocol to a single day requires validation with in vitro studies to demonstrate that most MNCs collected on the second day have already been inactivated, thereby making the second-day collection unnecessary. Such validation, provided clinical efficacy was not impaired, could result in the number of ECP procedures being reduced by 50%. This move would also have important consequences for policymakers. The cost of a multistep ECP protocol using Optia and the Macopharma ECP is approximately 500€ (250€ for the Optia set and 250€ for the Macogenic ECP treatment) versus 850€ for the single-step Cellex. The results of this study concerning MNCs collected and patient safety do not justify the higher cost of Cellex ECP. The multistep protocol, which we are still using in our center, could be reduced to a single day because the quantity of MNCs collected is very high compared with the singlestep method. However, the single-needle Cellex protocol is useful for patients with poor vein access because it avoids the use of a central catheter and could therefore be justified in our center.
Unanswered questions and future research
ECP protocols are usually defined according to the blood volume processed to collect a variable number of MNCs. 12, 13 However, the real objective should be a prefixed number of MNCs that we define as the MNC standard dose. This is a quantity of MNCs that has not been determined definitively in any study. The quantity of MNCs collected with the Optia protocol differs widely from that collected with Cellex. If the average of 18.5 × 10 8 MNCs collected with the Cellex protocol is sufficient to ensure clinical efficacy, we infer that the Optia protocol, which collects approximately four times this amount, seems much too high. What standard MNC dose should be collected by an ECP procedure to ensure the clinical efficacy of this treatment and, at the same time, avoid the unnecessary collection of extra MNCs? A recent publication discussed this topic and suggested that the number of MNCs collected has clinical relevance. 5 From the result of the two protocols in our study, we infer that, from a medical point of view, a standard dose of 25 × 10 8 MNCs could be considered conservative for ensuring therapeutic efficacy but is, however, much higher than the MNC dose proposed in previous studies. 5 We have calculated the time and blood volume needed to obtain our proposed 25 × 10 8 MNCs cell dose. From these data, we infer that both machines can collect such a dose when processing a similar blood volume (i.e., approximately 2500 mL in both protocols) and in a reasonable amount of time (78 minutes for Optia and 172 for Cellex). The same inference could be made regarding a higher standard dose of 40 × 10 8 MNCs ( Table 1 ) that could eliminate the need to perform ECPs on two consecutive days by collecting a higher amount of MNCs during a single ECP procedure. This strategy would improve patient comfort as well as reduce the cost of ECP treatments. In summary, we think that the multistep protocol offers a better MNC product for ECP at a lower cost. This comparative study also suggests that a shorter MNC collection procedure, or reducing the ECP procedure from two consecutive days to a single session, should be considered provided that therapeutic efficacy is not compromised. However, the single-step protocol with Cellex could be useful in patients with poor vein access because it avoids central catheters and their associated potential infections. Nevertheless, in our opinion, ECP protocols require further examination to establish a standard minimum number of MNCs collected to assure a higher clinical efficacy in our patients.
